Results 11 to 20 of about 2,402,468 (250)

Assessing Colorado’s Medication for Opioid Use Disorder (MOUD) Treatment Landscape, 2017-2021 [PDF]

Ann Fam Med, 2023
Emma Gilchrist
europepmc   +4 more sources

The impact of methamphetamine use on medications for opioid use disorder (MOUD) treatment retention: a scoping review [PDF]

Addiction Science & Clinical Practice, 2023
Abstract Background An emerging public health threat of methamphetamine/opioid co-use is occurring in North America, including increases in overdoses related to concomitant methamphetamine/opioid use. This presents a potential risk to established treatments for opioid use disorder (i.e., medications for opioid use ...
Cayley Russell, Justine Law, Sameer Imtiaz, Jürgen Rehm, Bernard Le Foll, Farihah Ali   +5 more
openaire   +4 more sources

Preliminary attitudes on medications for opioid use disorders (MOUDs) in Southeastern Switzerland and New York City

Journal of Addictive Diseases, 2022
The United States (US) and Switzerland are affluent countries with different responses to surges in opioid use disorder (OUD) cases over the last thirty years. The Swiss "PROVE" trail implemented heroin-assisted treatment (HAT) for OUD alongside other medications for opioid use disorder (MOUD).
Felipe Castillo, Daniel Scalise, David Hernandez, Rahul Gupta, Cale N. Basaraba, Thomas Corbeil, Sandra D. Comer, Andres R. Schneeberger   +7 more
openaire   +6 more sources

Primary Care Addiction Consultation Service: Colorado’s Implementation Support for Medication for Opioid Use Disorder (MOUD) [PDF]

Ann Fam Med
Tristen Hall, William Calawerts, Jacob Weiss, Kathy Cebuhar, Lauren Quintana, Chelsea Sobczak, Kimberly Wiggins   +6 more
europepmc   +4 more sources

Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis

International Journal of Drug Policy, 2023
In anticipation of COVID-19 related disruptions to opioid use disorder (OUD) care, new provincial and federal guidance for the management of OUD and risk mitigation guidance (RMG) for prescription of pharmaceutical opioids were introduced in British Columbia, Canada, in March 2020.
M. Eugenia Socias, Jin Cheol Choi, Nadia Fairbairn, Cheyenne Johnson, Dean Wilson, Kora Debeck, Rupinder Brar, Kanna Hayashi   +7 more
openaire   +3 more sources

Patient decision aid for medication treatment for opioid use disorder (PtDA-MOUD): Rationale, methodology, and preliminary results [PDF]

Journal of Substance Abuse Treatment, 2020
As treatment for opioid use disorder (OUD) expands within general healthcare settings such as primary care, mechanisms to facilitate decision-making processes are increasingly necessary. Decision aids have the capacity to bolster existing resources in diverse treatment settings by increasing knowledge of treatment options and facilitating shared ...
Jonathan Valdez, Sarah J. Cousins, Yuhui Zhu, Yih-Ing Hser, Caroline Yoo, Larissa J. Mooney, Larissa J. Mooney   +6 more
openaire   +6 more sources

Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system

Preventive Medicine, 2019
In 2013, Vermont leaders implemented the "hub-and-spoke" (H & S) system to increase access to medication treatment for opioid use disorder (MOUD). "Hubs" are licensed specialty opioid treatment programs (OTPs) with the authority to dispense buprenorphine/naloxone and methadone.
Michael McCann, Sarah J. Cousins, Regina Pearce, Traci Rieckmann, Richard A. Rawson, Richard A. Rawson   +5 more
openaire   +7 more sources

Nurse prescribing practices across the globe for medication-assisted treatment of the opioid use disorder (MOUD): a scoping review [PDF]

Harm Reduction Journal, 2023
Abstract Background Despite the dramatic increase in opioid-related deaths in recent years, global access to treatment remains poor. A major barrier to people accessing Medication-assisted treatment of the opioid use disorder (MOUD) is the lack of providers who can prescribe and monitor MOUD.
Sonam Prakashini Banka-Cullen, Catherine Comiskey, Peter Kelly, Mary Beth Zeni, Ana Gutierrez, Usha Menon   +5 more
openaire   +4 more sources

“You’re Not Supposed to be on it Forever”: Medications to Treat Opioid Use Disorder (MOUD) Related Stigma Among Drug Treatment Providers and People who Use Opioids [PDF]

Substance Abuse: Research and Treatment, 2022
Opioid use disorder (OUD) through prescription opioid misuse, heroin, and illicitly manufactured fentanyl use has increased dramatically in the past 20 years. Medications to treat opioid use disorder (MOUD) is considered the gold standard for treating opioid use disorders but uptake remains low.
Julia Dickson-Gomez, Antoinette Spector, Margaret Weeks, Carol Galletly, Madelyn McDonald, Helena Danielle Green Montaque   +5 more
openaire   +4 more sources

Prevalence, patterns, and predictors of prescribing medications for opioid use disorder (MOUD) in the Inpatient setting

Drug and Alcohol Dependence Reports
BACKGROUND: There are many barriers to prescribing medications for opioid use disorder (MOUD). This study evaluates the prevalence, patterns, and predictors of inpatient MOUD prescribing at discharge to patients with a diagnosis of opioid use/opioid use disorder (OUD) that developed opioid withdrawal during their hospital stay.
Ashley Burke, Nina Vadiei, Lea Mollon
openaire   +3 more sources